

# **Stimulation Therapy to Induce Mothers (STIM): Protocol for a Multicenter Randomized Controlled Trial**

Danna Tortal, Veronika Shabanova, Sarah Taylor, Xiao Xu, Molly McAdow,  
Bethany Stetson, Sarah McCollum, Ester Sanchez, Amie Adjakple, Jessica  
Leventhal, Moeun Son

Submitted to: JMIR Research Protocols  
on: June 20, 2024

**Disclaimer:** © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript..... 5

Supplementary Files..... 41

    Multimedia Appendixes..... 42

        Multimedia Appendix 1..... 42

# Stimulation Therapy to Induce Mothers (STIM): Protocol for a Multicenter Randomized Controlled Trial

Danna Tortal<sup>1</sup> BA; Veronika Shabanova<sup>2</sup> PhD; Sarah Taylor<sup>1</sup> MD; Xiao Xu<sup>3</sup> PhD; Molly McAdow<sup>1</sup> MD, PhD; Bethany Stetson<sup>4</sup> MD; Sarah McCollum<sup>2</sup> MPH; Ester Sanchez<sup>5</sup> BSN; Amie Adjakple<sup>1</sup> BS; Jessica Leventhal<sup>2</sup> DNP; Moeun Son<sup>6</sup> MD, MSci

<sup>1</sup>Yale School of Medicine New Haven US

<sup>2</sup>Yale University New Haven US

<sup>3</sup>Columbia University Vagelos College of Physicians and Surgeons New York US

<sup>4</sup>Northwestern University Feinberg School of Medicine Chicago US

<sup>5</sup>Weill Medical College of Cornell University New York US

## Corresponding Author:

Moeun Son MD, MSci

## Abstract

**Background:** Over 1 million women have their labor induced in the United States each year, and synthetic oxytocin infusion is the most common method used. However, compared to spontaneous labor, medical induction is resource-intensive, has increased obstetric risks, and is associated with less successful breastfeeding. In contrast to endogenous oxytocin hormone which is released in a pulsatile fashion in the brain, synthetic oxytocin is continuously infused intravenously, resulting in important limitations related to efficacy, safety, and cost. Akin to spontaneous labor contractions, infant suckling of the breast nipple is known to stimulate the pulsatile release of endogenous oxytocin from the posterior pituitary gland. Nipple stimulation therapy via electric breast pump similarly stimulates endogenous oxytocin release and may be a favorable inpatient method for patients undergoing labor induction.

**Objective:** To examine whether inpatient nipple stimulation therapy is an efficacious labor induction method that increases the likelihood of spontaneous vaginal delivery and sustained breastfeeding and determine whether it is a cost-effective approach.

**Methods:** This is a multicenter, pragmatic, open-label, parallel group randomized trial of nulliparous patients with singleton gestations ≥36 weeks undergoing labor induction. This trial compares inpatient nipple stimulation therapy via electric breast pump versus immediate synthetic oxytocin infusion without nipple stimulation. This trial of 988 nulliparas will provide adequate statistical power to detect clinically meaningful differences in delivery mode and breastmilk as the sole source of nutrition for newborns at hospital discharge or 72 hours of birth.

**Results:** The project received pilot funding in 2021 and full funding in 2023. Enrollment began in November 2021 at a single site and is now being conducted at three recruiting sites. It is anticipated that enrollment will be completed in late 2026.

**Conclusions:** Successful completion of this trial will provide rigorous data to determine whether inpatient nipple stimulation therapy with an electric breast pump can improve the way we induce labor and positively impact breastfeeding success and early infant nutrition through lactation. Clinical Trial: ClinicalTrials.gov NCT05079841

(JMIR Preprints 20/06/2024:63463)

DOI: <https://doi.org/10.2196/preprints.63463>

## Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

✓ **Please make my preprint PDF available to anyone at any time (recommended).**

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.

Only make the preprint title and abstract visible.

No, I do not wish to publish my submitted manuscript as a preprint.

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain v

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in <http://www.jmir.org/preprint/63463>



## Original Manuscript

# Stimulation Therapy to Induce Mothers (STIM): Protocol for a Multicenter Randomized Controlled Trial

Danna Tortal, BA<sup>1</sup>

Veronika Shabanova, PhD<sup>2,3</sup>

Sarah Taylor, MD<sup>2</sup>

Xiao Xu, PhD<sup>1,4</sup>

Molly McAdow, MD, PhD<sup>1</sup>

Bethany Stetson, MD<sup>5</sup>

Sarah McCollum, MPH<sup>2</sup>

Ester Sanchez, BSN<sup>6</sup>

Amie Adjakple, BS<sup>1</sup>

Jessica Leventhal, DNP<sup>7</sup>

Moeun Son, MD, MSCI<sup>1,6</sup>

<sup>1</sup>Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine

<sup>2</sup>Department of Pediatrics, Yale School of Medicine

<sup>3</sup>Department of Biostatistics, Yale School of Public Health

<sup>4</sup>Department of Obstetrics and Gynecology, Columbia University Vagelos College of Physicians and Surgeons

<sup>5</sup>Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine

<sup>6</sup>Department of Obstetrics and Gynecology, Weill Medical College of Cornell University

<sup>7</sup>Yale Center for Clinical Investigation, Yale School of Medicine

**Corresponding Author:**

Moeun Son, MD, MSCI

[Mos7003@med.cornell.edu](mailto:Mos7003@med.cornell.edu)

413 East 69<sup>th</sup> Street

Suite 16-086

New York, NY 10021

**Acknowledgements:**

The authors would like to acknowledge Denise Esserman, PhD (Yale University) for her assistance in preparing the randomization scheme for the trial. The authors would also like to acknowledge Aisha Owens, BS (Northwestern University), Alexa Stufano, BS, MPH (Weill Medical College of Cornell University), and Jenna Gartner, BA, BSN (Yale University) for their assistance in setting up each clinical study site. Support for this work has been provided by the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH) through grant R01 HD111633 awarded to M.S. Support was also provided by the Yale University Albert McKern Scholar Award awarded to M.S. The content is the sole responsibility of the authors and does not necessarily represent the official views of the NIH. Views expressed by the authors in the publication regarding EQ5-D<sup>©™</sup> and EQ-TIPS<sup>©™</sup> questionnaires do not necessarily reflect the views of EuroQol.

**Conflicts of Interest:** None

**Abstract word count:** 319

**Manuscript word count:** 6925

## Abstract

**Background:** Over 1 million women have their labor induced in the United States each year, and synthetic oxytocin infusion is the most common method used. However, compared to spontaneous labor, medical induction is resource-intensive, has increased obstetric risks, and is associated with less successful breastfeeding. In contrast to endogenous oxytocin hormone which is released in a pulsatile fashion in the brain, synthetic oxytocin is continuously infused intravenously, resulting in important limitations related to efficacy, safety, and cost. Akin to spontaneous labor contractions, infant suckling of the breast nipple is known to stimulate the pulsatile release of endogenous oxytocin from the posterior pituitary gland. Nipple stimulation therapy via electric breast pump similarly stimulates endogenous oxytocin release and may be a favorable inpatient method for patients undergoing labor induction.

**Objective:** To examine whether inpatient nipple stimulation therapy is an efficacious labor induction method that increases the likelihood of spontaneous vaginal delivery and sustained breastfeeding and determine whether it is a cost-effective approach.

**Methods:** This is a multicenter, pragmatic, open-label, parallel group randomized trial of nulliparous patients with singleton gestations  $\geq 36$  weeks undergoing labor induction. This trial compares inpatient nipple stimulation therapy via electric breast pump versus immediate synthetic oxytocin infusion without nipple stimulation. This trial of 988 nulliparas will provide adequate statistical power to detect clinically meaningful differences in delivery mode and breastmilk as the sole source of nutrition for newborns at hospital discharge or 72 hours of birth.

**Results:** The project received pilot funding in 2021 and full funding in 2023. Enrollment began in November 2021 at a single site and is now being conducted at three recruiting sites. It is anticipated that enrollment will be completed in late 2026.

**Conclusions:** Successful completion of this trial will provide rigorous data to determine whether inpatient nipple stimulation therapy with an electric breast pump can improve the way we induce



labor and positively impact breastfeeding success and early infant nutrition through lactation.

**Trial**                      **Registration:**                      ClinicalTrials.gov                      NCT05079841  
(<https://clinicaltrials.gov/study/NCT05079841>)



## Introduction

### *Background*

Of the roughly four million births in the United States (U.S.) each year, more than one million women have their labor medically induced in the hospital [1]. Synthetic oxytocin infusion is the most common method used currently to induce labor [2]. At the molecular level, synthetic oxytocin is identical to endogenous oxytocin [3] and is therefore effective at stimulating uterine contractions [2-4]. But synthetic oxytocin has important shortcomings. First, it is designated as a “high alert” medication [5] and requires strict oversight by the medical team for safety concerns [6-8], which is resource intensive. Second, unlike endogenous oxytocin, which is released in a pulsatile fashion, synthetic oxytocin is infused continuously, which can induce down-regulation of oxytocin receptors in myometrial muscle and result in reduced efficacy [9]. Third, compared to spontaneous labor, induced labor is associated with increased risks of operative delivery, postpartum hemorrhage, and other obstetric complications, especially when oxytocin use is prolonged [10, 11]. Fourth, synthetic oxytocin is infused into the peripheral circulation and minimally penetrates the blood- brain barrier [12], which precludes it from mimicking the other physiological benefits of endogenous oxytocin [13].

In contrast to synthetic oxytocin, breast nipple stimulation therapy induces a physiological process by stimulating the pulsatile release of endogenous oxytocin hormone from the pituitary gland. Pulsatile stimulation of oxytocin [14] mimics physiological labor, which could prove nipple stimulation to be a more efficacious method of labor induction compared to continuous infusion of synthetic oxytocin. More efficient labor typically results in improved obstetric outcomes, including an increased likelihood of a spontaneous vaginal delivery. Additionally, just as infant suckling of the breast nipple triggers postpartum lactation by inducing the milk ejection reflex [15], our pilot feasibility study found that nipple stimulation therapy via electric breast pump results in early

colostrum production and milk letdown during labor in many women, including nulliparas [16].

Breastfeeding has many known short and long-term benefits, but early discontinuation is common [17]. Breastfeeding protects against gastroenteritis, lower respiratory infection, and other infectious diseases in infancy [18-22]. Sustained breastfeeding promotes the infant's sensory and cognitive development [23], and protects the infant from chronic diseases [20, 24]. Further, a history of lactation is associated with reduced maternal risks of type 2 diabetes and breast and ovarian cancer [24]. No breastfeeding or early cessation is associated with increased risks for postpartum anxiety and depression [24-26]. Given these benefits, the World Health Organization [27], the Centers for Disease Control and Prevention (CDC) [28], and the American Academy of Pediatrics [29] all recommend exclusive breastfeeding without any supplementary formula or water from birth until six months of age. However, based on U.S. data from the CDC, although 84% of infants started breastfeeding, 20% were supplemented with formula before two days of age, and only 25% were exclusively breastfeeding at six months as recommended [17]. Maternal perception of insufficient milk supply and infant weight loss are the most common reasons reported for early breastfeeding cessation [30-32]. While almost all newborns lose weight after birth due to diuresis and low enteral intake [33], it is more pronounced in those who exclusively breastfeed [33-36]. The trajectory of newborn weight loss becomes the basis for multiple clinical decisions including timing of hospital discharge, need for lactation support or supplementation, and timing and type of newborn follow-up [37, 38]. A poor weight trajectory can be especially detrimental to maternal confidence [39, 40], and low breastfeeding confidence in the first week postpartum predicts early cessation [41, 42].

Therefore, the purpose of our multicenter clinical trial is to test the central hypothesis that intrapartum nipple stimulation therapy via electric breast pump will positively alter the childbirth

and early postpartum experience by increasing the likelihood of spontaneous vaginal delivery and exclusive and sustained postpartum lactation. Further, studies have shown that strategies that increase likelihood of vaginal delivery can have significant impact on public health and cost [43]. In addition, increasing breastfeeding rates would reduce reliance on infant formula and potentially reduce healthcare utilization during the early newborn period. The potential economic and public health impacts of our intervention on the success of breastfeeding and subsequent maternal and infant health are also substantial [44, 45], and therefore we are also examining the cost-effectiveness of this intervention.

### ***Aims and Hypotheses***

The STIM (Stimulation to Induce Mothers) trial was designed to pursue three aims. First, we aim to compare the effect of inpatient nipple stimulation therapy via electric breast pump versus synthetic oxytocin infusion without nipple stimulation (comparator) on delivery method. We hypothesize that those randomly assigned to nipple stimulation therapy will be more likely to achieve spontaneous vaginal delivery and have less labor-related complications compared to those in the comparator group. Second, we aim to compare the effect of inpatient nipple stimulation therapy via electric breast pump versus synthetic oxytocin infusion without nipple stimulation (comparator) on postpartum lactation. We hypothesize that those randomly assigned to nipple stimulation therapy during labor will be more likely to use breastfeeding as the sole source of nutrition at hospital discharge, which will be associated with improved maternal perception of milk supply, less severe newborn weight loss, and sustained breastfeeding for the recommended 6 months. Third, we aim to examine the cost-effectiveness of inpatient nipple stimulation therapy via electric breast pump, in comparison to synthetic oxytocin infusion without nipple stimulation (comparator). By examining cost of care and health-related quality of life, we hypothesize that

performing nipple stimulation therapy during labor will be more cost-effective than the comparator after considering their overall impact on labor and delivery, breastfeeding, and early infant nutrition and care in the first 6 months.

## **Methods**

### ***Overview and Study Design***

STIM is a multicenter, pragmatic, open label, parallel group randomized controlled trial of nulliparas to compare the effectiveness of inpatient nipple stimulation therapy with or without adjunctive synthetic oxytocin (intervention) versus immediate synthetic oxytocin infusion without nipple stimulation (comparator) during labor induction. Randomly allocating participants to different interventions minimizes selection bias and results in groups that are comparable with regards to important confounding variables, both measured and unmeasured. A pragmatic trial design was selected so that study findings, if positive, can be directly applied and disseminated quickly and widely in the “real world.” We will follow the Consolidated Standards of Reporting Trials (CONSORT) guidelines wherever appropriate in the conduct and reporting of this trial [46]. The use of broad eligibility criteria, the simplicity and low cost of the study intervention, and the multicenter design with patient diversity increases generalizability and will promote direct application of the findings.

### ***Ethics Approval and Consent to Participate***

This study is approved by the Yale University Institutional Review Board (IRB) which serves as the single IRB. The study is approved by the Weill Cornell Medicine IRB and Northwestern University IRB with reliance agreements to the Yale University IRB. The study was registered in

Clinicaltrials.gov (NCT05079841) prior to study start. All study participants are required to sign a written informed consent form in English or Spanish to participate in study activities prior to their enrollment.

### ***Study Setting and Population***

There are three planned recruiting sites for the STIM trial: Yale New Haven Hospital (YNHH) in New Haven, Connecticut; the Alexandra Cohen Hospital for Women and Newborns at New York Presbyterian Hospital (NYP) - Weill Cornell Medicine in New York, New York; and the Prentice Women's Hospital at Northwestern Memorial Hospital (NMH) in Chicago, Illinois.

Eligible participants are identified among patients admitted to the labor and delivery units for planned delivery at each recruiting site. We are using broad inclusion criteria to ensure generalizability of our results. In brief, patients who are nulliparas with singleton gestations at 36 weeks 0 days and greater, aged 18 years or older, who are planned to undergo labor induction with synthetic oxytocin are eligible. Exclusion criteria are limited to conditions for which nipple stimulation, synthetic oxytocin, or labor attempt are contraindicated, or the fetus is thought to be at higher risk for admission to the neonatal intensive care unit after birth. More specific eligibility criteria are listed in Table 1.

### ***Study Interventions***

The active arm (study intervention) in this trial is intrapartum nipple stimulation therapy via electric breast pump (with or without adjunctive synthetic oxytocin). The control arm (current standard management) is immediate synthetic oxytocin infusion without nipple stimulation therapy as the comparator. Continuous fetal cardiotocography will be required in both treatment groups.

Active arm: nipple stimulation therapy via electric breast pump

Nipple stimulation therapy will be initiated in lieu of starting with synthetic oxytocin. There is no maximum length of time for which nipple stimulation can be continued if it is tolerated by the participant and her fetus. The study intervention requires a minimum of 2 hours of nipple stimulation therapy without synthetic oxytocin use to be considered valid. The 2-hour threshold was chosen because our preliminary data showed that it took a median of 69 (IQR 21-80) minutes for participants performing nipple stimulation therapy to have an “adequate” contraction pattern (defined as at least 3 contractions in a 10-minute period, averaged over >30 minutes) [16]. After at least 2 hours (excluding breaks) of nipple stimulation therapy, synthetic oxytocin infusion may be initiated as part of a step-up treatment strategy if desired by the participant or by their primary obstetric clinician. Synthetic oxytocin infusion can be initiated as an adjunct to continued nipple stimulation therapy or can be used as a replacement. In such cases, synthetic oxytocin will be infused according to each study site’s hospital protocol. If synthetic oxytocin infusion is initiated <2 hours (excluding breaks) of attempting nipple stimulation therapy, this will be considered a cross-over. The time spent performing nipple stimulation therapy will be recorded in 2 ways using methods of data collection that were validated in the pilot feasibility study [16]: 1) participants and/or their labor support person(s) will complete a study “diary” to record start and stop times, mark unilateral or bilateral nipple stimulation, and record suction settings; and 2) per hospital protocol at all study sites, the labor nurse assesses the patient and reviews the fetal cardiotocography every 15-30 minutes and records the method of labor induction (i.e. nipple stimulation, synthetic oxytocin, or both) as well as their interpretation of the fetal cardiotocography in the electronic medical record (EMR). In addition, the labor nurse documents the start and stop times of any labor induction agent (i.e. nipple stimulation, synthetic oxytocin, etc.) in the EMR as per hospital

protocol.

Participants randomized to the active arm will be provided with a hospital-grade electric breast pump (Medela Symphony<sup>®</sup> at YHH and NYP and Ameda Platinum<sup>®</sup> at NMH), its accessories, as well as a hands-free pumping bra, and will receive a tutorial from their labor nurse. Additional support will be available from the hospital lactation consultants at all study sites. Both electric pump types utilize technology that mimics an infant's natural sucking rhythm with two distinct phases: the stimulation phase to emulate the initial light but fast sucking to start milk flowing followed by the expression phase which emulates slower deep suck to bring out more milk faster. Nipple stimulation will be initiated on a single breast until uterine contractions are elicited and are occurring at least every 3 minutes by patient report or based on tocodynamometer. If stimulation of either breast does not result in the desired contraction pattern after 30 minutes, stimulation of bilateral breasts will be attempted. Therapy will be performed continuously with the pump suction set to the pressure (mm Hg) most tolerated by the participant and can be self-adjusted by the participant. Like how synthetic oxytocin is infused and titrated, nipple stimulation therapy will be "titrated" based on the fetal cardiotocography. If there are more than 5 contractions in 10 minutes, the pump suction setting will be reduced or turned off until the contraction pattern is in the desired range to avoid tachysystole. If uterine contractions start to occur less than every 3 minutes by patient report or based on tocodynamometer, the pump suction setting will be increased or turned back on (if it had been turned off) until the desired contraction pattern is obtained again. The pump can be temporarily turned off or the suction settings can be temporarily decreased per patient request even if the contraction pattern is in the desired range, but not recommended for longer than 15 minutes at a time.

Comparator arm: Immediate synthetic oxytocin infusion without nipple stimulation therapy



Participants randomized to the control arm will receive immediate synthetic oxytocin infusion, which is administered and dosed according to each study site's protocol. All recruiting sites will use an oxytocin dosing protocol with an initial and incremental dose rate increase of 2 mU/min. Premixed oxytocin intravenous solutions are infused via a programmed smart pump. Dosage may be increased every 15 to 40 minutes, depending on the hospital site. The oxytocin maximum infusion dose rate differs at each study site per hospital policy: 20 mU/min at YNHH and 40 mU/min at NYP and NMH. Rate changes or discontinuation of oxytocin administration are based on the assessment of the following: fetal status, contraction status, and maternal coping. Per protocol at all study sites, the labor nurse assesses the patient and reviews the fetal cardiotocography every 15-30 minutes and records the method of labor induction (i.e. synthetic oxytocin) as well as their interpretation of the fetal cardiotocography in the EMR. In addition, the labor nurse documents the start and end times of any labor induction agent (i.e. synthetic oxytocin) in the EMR as per hospital protocol. If nipple stimulation is performed at any time, this will be considered a cross-over.

### ***Additional Study Procedures***

For participants assigned to nipple stimulation therapy, those who express colostrum or breastmilk during the stimulation process can collect and store it for postnatal feeding. Supplies for safe collection and storage are provided. All participants, regardless of group assignment, are asked to report their pain score prior to and 1 hour after intervention start using the visual analog scale [47]. In addition, all participants, regardless of group assignment, are asked to complete electronic surveys at 5 different study timepoints: at time of enrollment, 1-3 days postpartum, 2 weeks postpartum, 4-12 weeks postpartum, and 6 months postpartum (Table 2). Surveys are administered using the REDCap (Research Electronic Data Capture) survey tool, and weblinks and QR codes are

provided to participants via email or text message (whichever the participant prefers). Paper versions and survey administration via phone call are also available if requested.

### ***Recruitment, Assignment, and Allocation***

All patients who are scheduled for labor induction or are admitted to the hospital's labor and birth unit to undergo labor induction are screened for study eligibility by a trained member of the investigative team. With the assent of their primary obstetric clinician, patients meeting eligibility criteria are approached for potential recruitment. The study is explained in detail and all questions will be answered prior to signing written informed consent to participate in the study. Patients can be consented prior to completion of cervical ripening (if cervical ripening is needed) but will not be randomized until the medical team confirms that the patient's cervical exam has Bishop score  $\geq 5$  (if membranes intact) or membranes are ruptured, and the patient is ready to start oxytocin and therefore eligible for randomization.

At each study site, enrolled participants are randomly assigned in a 1:1 ratio to both study groups. A web-based randomization sequence was prepared by an independent statistician using blocks of variable sizes, stratified by study site and amniotic membrane status (intact versus ruptured). The advantage of this method is that it provides a good probability of balance, and future assignments are unpredictable. A participant's group assignment is obtained only after the participant is confirmed to continue to meet inclusion criteria, and a study number is entered and locked in using REDCap. Although blinding of participants and their obstetric teams would be ideal, blinding is clearly not possible in this trial. We will minimize systematic bias by applying the same standard procedures for other labor and management strategies between groups at each study site. Further, the group assignment of participants will not be considered by study staff collecting

maternal and neonatal outcomes. Importantly, the main outcomes of spontaneous vaginal delivery and exclusive breastfeeding at hospital discharge are objective measures.

### **Study Outcomes**

The primary outcome (Aim #1) is spontaneous vaginal delivery, defined as delivery without the use of forceps, vacuum, or cesarean, as it is the most desirable obstetric outcome for laboring women. Compared to a cesarean, spontaneous vaginal delivery is associated with lower maternal and neonatal morbidity, including hemorrhage, wound infection, endometritis, and prolonged hospitalization [48]. Further, once a primary cesarean is performed, the risk of delivery by cesarean for future pregnancies is significantly increased [49], further escalating maternal morbidity. Although operative vaginal delivery (i.e., forceps or vacuum) is associated with lower maternal morbidity compared to cesarean, it carries higher risks for maternal pelvic floor and neonatal injury than spontaneous vaginal delivery [50]. Secondary outcomes (Aim #1) include time to delivery among those who achieve spontaneous vaginal delivery, cesarean delivery, operative vaginal delivery, intraamniotic infection or postpartum endometritis, and postpartum hemorrhage. Labor agency [51], birthing experience satisfaction [52, 53], and depression scale [54] scores will also be examined.

The main outcome for Aim #2 is breastfeeding as the sole source of nutrition (BSSN) at the time of delivery hospitalization postpartum discharge or within the first 72 hours. This timepoint is chosen because it is the most likely to be causally linked to the study intervention, avoids the risk of attrition bias, and predicts the likelihood of sustained breastfeeding for the recommended 6 months postpartum [55]. BSSN is defined as the infant receiving breastmilk without any supplementary formula or water within the first 72 hours of life. Infant feeding method (breastmilk

only, mixed feeding which includes both breastmilk and infant formula, or infant formula only) is standardly documented in the EMR at least daily until day of birth hospitalization discharge, and these data will be abstracted from the EMR by trained study staff. The baseline strength of breastfeeding intention will be assessed using a validated Infant Feeding Intentions Scale (IFI) [56, 57] at the time of trial enrollment. The total score of the 5-question IFI ranges from 0 (very strong intention not to breastfeed at all) to 16 (very strong intentions to provide breastmilk as sole source of milk for first 6 months). Secondary outcomes (Aim #2) include maximal percent newborn weight loss within the first 72 hours of life, patient-reported perception of insufficient milk supply in early lactation, patient-reported satisfaction with breastfeeding, and the rate of sustained breastfeeding for the recommended 6 months postpartum. These secondary outcomes are chosen to explore potential reasons if, as we hypothesize, there are differences seen in BSSN or sustained breastfeeding. Maximal percent newborn weight loss is defined as the difference between birth weight and the lowest weight recorded subsequently up to 72 hours of age during the birth hospitalization, calculated as a percentage of the birth weight, as is typically done daily in clinical practice. It is standard hospital practice at all study sites to regularly weigh each newborn during their birth hospitalization. Infants are weighed naked using a digital scale, and the weight is expressed in kilograms. At all study sites, newborns are weighed at birth and then at least daily until day of discharge. The second weight measured after birth is usually performed after at least 6 hours post-birth. Weighing is typically discontinued if the newborn regains his or her birth weight prior to discharge. Infant birth weights are recorded in a standardized fashion in specific EMR flowsheets at all study sites. The date and time of each weight are recorded which allows calculation of precise age at time of weight. Patient-reported perception of insufficient milk supply will be assessed using the validated Perception of Insufficient Milk Supply (PIMS) survey [58]. The 14-question PIMS uses a Likert scale for each statement, and all responses are grouped into positive (consistent with a

perception of adequate milk supply) and negative (consistent with PIMS) responses. Patient-reported satisfaction with breastfeeding will be assessed using the validated Maternal Breastfeeding Evaluation Scale (MBFES) [59, 60]. The total score of the 30-question MBFES ranges from 30 to 150, with higher scores reflecting greater satisfaction, indicating positive evaluation of the breastfeeding experience. To assess continuation of breastfeeding at 6 months postpartum, participants are asked via survey whether they are exclusively breastfeeding, mixed feeding with breastmilk and formula, or exclusively formula feeding.

Outcomes assessed in Aim 3 include: 1) cost of relevant care and 2) health-related quality of life. Both outcomes will be measured for the mother-infant pair. Cost of care will include direct medical cost, direct non-medical care, and indirect cost. Direct medical cost will encompass hospital facility costs and provider professional fees associated with relevant care (maternal labor and delivery hospitalization, newborn's initial birth hospitalization, maternal postpartum care, and infant's postnatal pediatric visits). Direct non-medical cost will account for breast pump use at home, infant formula use, and transportation to relevant care. Indirect cost (i.e., maternal productivity loss) will measure participants' work loss in the postpartum period based on income and employment survey questions. As the project will span multiple years, we will use consumer price index to inflation adjust all cost estimates to a constant year US dollar [61]. Health-related quality of life for participants will be measured by the EuroQoL five dimensions (EQ-5D<sup>®</sup>) instrument [62]. EQ-5D<sup>®</sup> is a validated instrument for measuring and valuing health. It includes a descriptive system assessing five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), along with a visual analogue scale (EQ VAS) assessing overall health ranging from worst to best imaginable health. Response to each dimension includes five severity levels (no, slight, moderate, severe, or extreme problems). Participants' response to

the five dimensions of the EQ-5D<sup>™</sup> descriptive system will be converted to a utility score using a validated U.S. population-based algorithm [63]. Utility score takes values ranging from 0 to 1, with 0 referring to a health state equivalent to death and 1 equivalent to perfect health. EQ-5D<sup>™</sup> is a recommended and widely used instrument for measuring utility score in clinical trials and in maternal health research [64, 65]. For infants, the South Africa (English) EQ-TIPS<sup>™</sup> Paper Proxy 1 questionnaire (previously known as Toddler and Infant (TANDI) Health Related Quality of Life [66]) is completed by participants (as proxy reporters for their infants). This questionnaire has been shown to be valid and reliable for use in very young children [66]. It contains a six-dimension descriptive system (movement, play, pain, social interaction, communication, and eating) with three severity levels (no, some, or a lot of problems), along with a visual analogue scale (VAS) assessing an infant's overall health. As an algorithm for calculating utility scores based on the EQ-TIPS<sup>™</sup> descriptive system is not available yet, we anticipate using a linearly transformed VAS score to approximate a utility score on a 0 to 1 scale.

### ***Data Collection and Management***

Labor course and outcome data of randomized participants and their newborns are collected by study staff through direct interview and chart review of the EMR. Data are collected on standardized forms in REDCap, an established, secure, web-based capture and management tool developed at Vanderbilt University and supported by the Yale Center for Clinical Investigation (<https://redcapynh.ynhh.org/>), on which nearly all responses are pre-coded.

All participants will be assessed for Aims 1 and 2 and their secondary outcomes. Maternal follow-up will occur until 6 months postpartum. We expect that all participants will be included for the co-primary outcomes as all study sites provide maternity and newborn care with the highest levels designated by each respective state (Connecticut, New York, and Illinois), and early out-of-

hospital transfers are not expected. Aim 3 will include all participants and newborns with complete cost data, with regular follow-up for up to 6 months.

Data on cost of care will be collected from multiple sources. First, accounting databases are available at all study sites and utilize advance platforms allowing for extraction of detailed data on hospital facility costs. Physician professional fees data will also be extracted for services provided by physicians and other practitioners. If these data are not accurately available, relevant fee schedules from the Centers for Medicare and Medicaid Services (CMS) [67] will be used alternatively. Hospital facility costs and physician professional fees will be determined for the delivery hospitalization encounters of the participants and the birth hospitalization encounters of their newborns. As hospital-grade electric breast pumps are multi-user pumps, its cost for each participant will be allocated based on duration of use and the expected total life span of the pump. Second, the cost of medical care after hospital discharge will be based on a roster of outpatient visits, emergency department visits, and re-hospitalizations for both participants and their newborns. Third, participants are asked to complete surveys to report personal income, education level, employment status and return to work, workplace absenteeism and presenteeism and household productivity loss, infant formula use, and breast pump use at home. Fourth, travel cost for the care of participants and their newborns will be estimated based on roundtrip miles between home zip code and the zip codes of the postpartum care office and the pediatrician's office.

### ***Sample Size and Power***

The sample size for the trial is based on the primary outcome of spontaneous vaginal delivery for Aim 1 (Table 3). All sample size and power estimates are based on two-tailed tests. This is important because we will be powered to detect both increases and decreases in outcomes with intrapartum nipple stimulation therapy (intervention) versus immediate synthetic oxytocin infusion

without nipple stimulation (comparator). The expected rate of spontaneous vaginal delivery in the setting of immediate synthetic oxytocin infusion without nipple stimulation used for the sample size estimation is based on averaged institutional data from the three study sites:  $(62\%+66\%+70\%)/3=66\%$ . Accounting for a 5% attrition rate, we estimate that a total of 988 (494 nipple stimulation therapy and 494 immediate synthetic oxytocin infusion without nipple stimulation) will be sufficient to detect a minimum of 9.8% absolute difference (estimated 75.8% with nipple stimulation therapy versus 66.0% in the comparator group) in spontaneous vaginal delivery with 90% power (two-sided alpha of 0.05). Of note, 80% statistical power would be needed to detect a minimum absolute difference of 8.6% (74.6% vs. 66.0%).

At first glance, the anticipated minimum ~10% or greater absolute increase in the spontaneous vaginal delivery rate in our proposed trial appears modest. On the contrary, because the potential public health impact is large, this effect size is significant. It is estimated that 40% of the one million women who undergo inpatient labor induction each year in the US are nulliparas. Therefore, a minimum of ~10% increase in spontaneous vaginal delivery translates to 40,000 more spontaneous vaginal deliveries and 40,000 fewer operative and cesarean deliveries each year. Avoiding 40,000 operative or cesarean deliveries each year will have substantial impact on overall morbidity and healthcare resource utilization in the US and can have broad implications beyond the U.S.

The sample size of 988 for the primary outcome will be sufficient to detect a 9.4% or 10.8% absolute difference in breastfeeding as the sole source of nutrition (BSSN) at the time of delivery hospitalization postpartum discharge with 80% power and 90% power, respectively (two-sided test,  $\alpha=0.05$ ). This represents the difference between an expected BSSN rate of 45.5% in the setting of synthetic oxytocin infusion without nipple stimulation (average rate at the three study sites based on institutional data:  $(44\%+50\%+42.5\%)/3=45.5\%$ ) and 54.9% (with 80% power) or 56.3% (with 90% power) with nipple stimulation therapy.



Assuming a 15% attrition rate at 2 weeks postpartum (the time frame for our primary cost-effectiveness analysis in Aim 3), the sample size of 988 will have 90% power for detecting a standardized effect size of 0.224 (0.194 for 80% power) for the between-group difference in cost and difference in quality adjusted life years (QALY) (two-sided test,  $\alpha=0.05$ ). This is considered a small effect size based on conventional criteria, hence if we observe an even larger effect size, we should be sufficiently powered [68].

### **Data Analysis Plan**

Analyses will follow the intention-to-treat principle in which subjects will be analyzed in the group to which they were randomized, regardless of whether they received the assigned intervention. Descriptive statistics will characterize the group of individuals recruited and investigate comparability of the two study groups at baseline. Formal statistical testing will be limited to select baseline characteristics considered to be prognostic factors for the primary outcome including hospital admission body mass index (BMI), primary indication for labor induction, Bishop score at randomization, and birth weight. Categorical variables will be compared between trial groups by using the Chi-squared or Fisher's exact tests as appropriate, and continuous variables will be compared using Student's t-tests or Wilcoxon Rank Sum tests, as appropriate. Distributions of continuous variables will be assessed by visual inspection of histograms.

The primary outcome (spontaneous vaginal delivery) and other categorical secondary outcomes will be compared between trial groups using Chi-square or Fisher's exact tests as appropriate. The estimates of the relative risk and 95% confidence intervals (95% CI) associated with the primary and secondary outcomes will be calculated using Agresti and Coull method. The time to event regression analyses for labor length (regardless of delivery mode) and labor length censored for cesarean will be evaluated by Kaplan-Meier estimates and plots, and tested with the log-rank test, whereas Cox proportional hazards analysis will be used in adjusted analyses accounting for Bishop

scores at study entry (proportionality assumption will be checked graphically with  $\ln(-\ln\text{Survival})$  plots), and results summarized using hazard ratios (HR) and 95% CI. A sensitivity analysis will be performed using the induction method that the patient actually received (per-protocol analysis) to determine whether crossovers influenced the results. The distribution of maximal percent newborn weight loss is not expected to follow a normal distribution in the population, so we plan to use Wilcoxon Rank Sum tests to compare the distribution of the maximal percent weight loss between treatment groups and summarize the results as medians (25<sup>th</sup> and 75<sup>th</sup> percentiles) and bootstrapped 95% CIs. Similarly, the distributions of the PIMS survey scores and MBFES survey scores are not expected to follow normal distributions in the population, so we will use Wilcoxon Rank Sum tests to compare the distribution of the MBFES scores between treatment groups and summarize the results using the group medians (25<sup>th</sup> and 75<sup>th</sup> percentiles) and bootstrapped 95% CIs.

### Adjusted Analyses

We will perform other analyses as needed aimed at obtaining adjusted assessments of treatment effectiveness, adjusting for baseline patient characteristics (covariates). The objectives of these analyses are to estimate the influence of covariates on the outcome and to use covariates to improve the estimated difference between treatment groups. The Poisson regression model (link=log) with robust standard errors stratified by study site will be used to identify and estimate the effect of multiple prognostic factors on the probability of spontaneous vaginal delivery and other categorical outcomes, with results summarized as adjusted risk ratios. For continuous secondary outcomes such as maximal newborn weight loss and PIMS and MBFES survey scores, quantile regression, e.g., modeling 50<sup>th</sup> percentile, will be considered to adjust for prognostic factors.

### Planned Subgroup Analyses

The following pre-specified subgroup analyses will be conducted: (1) study site; (2) amniotic membrane status (intact versus ruptured) at enrollment; (3) presence versus absence of maternal diabetes (inclusive of pre-gestational and gestational diabetes); (4) insurance type (commercial

versus public insurance); (5) maternal race (non-Hispanic Black versus non-Hispanic White versus Other); (6) obesity (obese versus non-obese). In separate models, each of these sub-group variables will be included as an additional covariate in the models for outcomes of interest, plus their interaction with treatment variable; followed by stratified analyses (by each of the above variables) of the effect of treatment on each outcome of interest.

### Cost-effectiveness analyses

Cost analyses will follow recommendations by the Second Panel on Cost-Effectiveness in Health and Medicine [69]. We will use both a societal perspective (include all costs and health effects regardless of who incurs such costs or effects) and the health care sector perspective (only include direct medical cost) to best inform decision-making. Costs will be categorized by phase/type of care (labor and delivery, newborn hospitalization, postnatal care, etc.) and then aggregated to calculate total cost for each participant-infant pair. Effectiveness of the intervention will be assessed using quality adjusted life years (QALY). QALY is calculated by weighting the duration of life years in each health state by its corresponding utility score. We will use utility score at the various assessment timepoints and use an area under the curve approach to calculate QALY [70]. QALY of each participant and her infant will be summed. Our primary analysis will examine costs and health effects up to 2 weeks postpartum (the time-period when the intervention is most influential on the outcomes and less likely to be confounded by other factors occurring postpartum). To capture potential longer-term impact, we will conduct a secondary analysis extending the time-period to 6 months postpartum. Since the analytical timeframe for a given participant is <1 year, we will not discount cost or QALY [69]. In addition, although EQ-5D has been demonstrated to adequately capture differences in women's quality of life between cesarean delivery and spontaneous vaginal delivery [65], there is some concern that the five dimensions of the EQ-5D descriptive system may not be very sensitive to other pertinent outcomes of labor induction [71]. Therefore, we will perform a sensitivity analysis using participants' EQ VAS rating as a utility score (with linear transformation

to a 0 to 1 scale), which presumably captures a participant's perceive overall health regardless of dimensions.

To estimate difference in cost and difference in effectiveness between the intervention and comparator groups, we will use a generalized linear model (GLM) with log link and gamma distribution for cost (given skewness in cost data) and identity link and normal distribution for QALY. The unit of analysis will be each participant-infant pair. Explanatory variable will be an indicator for intervention (vs. comparator) group. All analyses will follow the intention to treat principle. As randomization will be stratified by study site and amniotic membrane status, we will test if they are associated with cost or QALY and then decide whether to include them as covariates in analysis [72]. Cost effectiveness will be evaluated by calculating the incremental cost effectiveness ratio (ICER), defined as  $\Delta C/\Delta E$  where  $\Delta C$  denotes the estimated difference in cost between the intervention and comparator groups and  $\Delta E$  reflects the estimated difference in QALY between the two groups. ICER informs the additional cost associated with the intervention for each additional QALY gained. We will use non-parametric bootstrap resampling to estimate 95% CI of ICER and produce a cost-effectiveness plane and cost-effectiveness acceptability curve. In special situations where the intervention leads to significantly lower cost and higher QALY, the intervention is considered the dominating strategy. We will follow the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) to report the findings [73].

## Results

The project received pilot funding in 2021 and full funding in 2023. Enrollment began at YNHH in November 2021, NYP in April 2024, and NMH in May 2024. As of June 2024, 320 participants have been enrolled. We anticipate we will complete enrollment in late 2026 and we expect to submit initial results for publication in 2027.

## Discussion

### ***Strengths and Limitations***

With our robust and rigorous experimental design, this multicenter clinical trial will amplify and expand on prior research in several important ways. First, this trial is testing inpatient nipple stimulation therapy in a well-defined study population at multiple study sites which will optimize external validity and promote generalizability. Prior randomized studies included both nulliparas and multiparas [74, 75] or parity was not considered [76]. This is a severe limitation given well-known differences in labor patterns, childbirth outcomes, and familiarity with breastfeeding based on parity. Our feasibility study [16] piloted the intervention in both groups and found that nulliparas were similarly willing and able to perform nipple stimulation therapy during labor. Therefore, nulliparas were chosen as the population of interest for this proposal because they are at greater risk for failed labor induction and early breastfeeding discontinuation compared to multiparas, and therefore anticipated to reap the most potential benefit from the study aims. This trial also seeks to overcome the limited validity of prior studies in which eligibility criteria were poorly-defined [76] or too restrictive [75]. We will use eligibility criteria that are appropriately inclusive to maximize study recruitment and enhance generalizability but are also well-defined to minimize confounding factors and safeguard against harm.

Second, this trial is adequately powered to assess for clinically significant differences in two key outcomes. Three prior published randomized studies [74-76] comparing nipple stimulation versus synthetic oxytocin infusion were severely limited by small sample sizes (62 to 92 participants), and none of them examined postpartum breastfeeding. The planned sample size of 988 women will be adequately powered to detect clinically important differences in spontaneous vaginal delivery, a desirable labor outcome, and the rate of infants receiving breastmilk as their sole source of nutrition at hospital discharge, a desirable postpartum outcome.

Third, this trial investigates whether inpatient nipple stimulation therapy improves lactation

outcomes, and comprehensively explores potential reasons such as maternal perception of milk supply and severity of early newborn weight loss. One randomized trial [77] examined nipple stimulation via breast pump versus synthetic oxytocin in the third stage of labor (i.e., after birth of the newborn but before delivery of the placenta). They found that women who performed nipple stimulation were more likely to initiate breastfeeding in the first 24 hours after birth but did not examine whether breastfeeding was sustained past the first 24 hours. Alternatively, antenatal breastmilk expression before labor has also been studied as a method to promote breastfeeding and prevent complications such as hypoglycemia for newborns at increased risk (e.g., those born to diabetic mothers) [78]. However, the association between antenatal breastmilk expression and endogenous oxytocin release has raised concerns about the possible induction of premature labor. If true, a strategy that induces breastmilk expression hours prior to birth, like ours, may prove to be the ideal intervention.

Fourth, we will investigate the potential economic implications of this innovative study intervention. With the large number of births each year, identifying cost-effective obstetric interventions can have substantial public health and financial benefits. Inpatient nipple stimulation therapy is expected to be of low cost. Our rigorous collection and assessments of cost data along with participants' and infants' health-related quality of life, will contribute important information informing the cost-effectiveness of this novel intervention.

There are potential limitations that we continue to work to overcome. First, as with any prospective study, recruitment can be a challenge due to clinical volume fluctuation or low consent rates. With the recent addition of two recruiting sites (NYP and NMH) and the addition of more research staff to recruit during off-hours, we expect to readily achieve our planned sample size. Second, there is risk of cross-over for participants in the study intervention group if synthetic oxytocin is initiated prior to completing 2 hours of nipple stimulation. In our feasibility study [16],

the mean duration of nipple stimulation therapy was  $208 \pm 28$  minutes, or 3.5 hours and attrition rate in the nipple stimulation group was only 5%, which is already captured in our sample size calculation. In addition, sensitivity analysis will be performed to address potential cross-over. Participants in the intervention group can receive synthetic oxytocin as adjunctive therapy after 2 hours of nipple stimulation therapy without being considered a cross-over. Even if synthetic oxytocin is used adjunctively to nipple stimulation, this is not considered a failure of treatment because these two treatments likely work synergistically, and intrapartum nipple stimulation can still have other benefits aside from uterine contractions. Further, this is not likely to increase type I error, but in fact can skew our inference toward the null hypothesis or to the superiority of synthetic oxytocin infusion without nipple stimulation (comparator) since attempting nipple stimulation therapy would have only prolonged or complicated the labor induction process in cases in which it was unsuccessful. In a sensitivity analysis, we will obtain risk ratios by further re-categorizing our intervention by accounting the time to initiation of synthetic oxytocin as adjunctive therapy after at least 2 hours of nipple stimulation therapy. Third, nipple stimulation therapy is controlled by the participant, which will likely prove to be a major benefit of the therapy. However, measurement of the therapy relies somewhat on patient participation as they are asked to complete a standardized diary to track what they are doing. In our feasibility study [16], the diary completion rate was  $>90\%$ . In addition, per hospital protocol at all study sites, the labor nurses document the start and end times of any labor induction agent in the EMR. Therefore, measurement of adherence to study intervention protocol is expected to be reliable. Fourth, survey completion rates in our feasibility study [16] were high, however a higher than anticipated loss to follow-up is possible. While this will not impact our primary outcomes, incomplete data would affect secondary outcomes. Multiple strategies are in place, such as reminder text messages and follow-up phone calls to participants, to minimize missing data.

## Conclusions

The expected outcome of this clinical trial is that nipple stimulation therapy will improve labor and birth, breastfeeding, and early newborn hydration and nutrition, thereby decreasing health care costs. With over 1 million U.S. women medically induced every year, successful completion of this randomized trial will help address the need to improve induction methods and may offer an opportunity to positively impact the childbirth and postpartum experience.



## Tables

**Table 1. Eligibility criteria of the STIM trial**

Inclusion Criteria
<ul style="list-style-type: none"> <li>▪ Age <math>\geq 18</math> years</li> <li>▪ Nulliparous</li> <li>▪ Live singleton gestation <math>\geq 36</math> weeks</li> <li>▪ If amniotic membranes intact, modified Bishop score <math>\geq 5</math> and cervix <math>&lt; 6</math> cm dilated; use of cervical ripening agents (e.g., prostaglandins or intracervical balloon) prior to randomization is allowed</li> <li>▪ If amniotic membranes ruptured, <math>&lt; 3</math> contractions per 10-minute period averaged over 30 minutes regardless of cervical exam</li> <li>▪ Able to give informed consent</li> <li>▪ Able to understand and speak English or Spanish</li> </ul>
Exclusion Criteria
<ul style="list-style-type: none"> <li>▪ Presence of tachysystole, recurrent variable or late fetal decelerations, or fetal bradycardia within 30 minutes prior to enrollment</li> <li>▪ Non-vertex presenting fetus at enrollment</li> <li>▪ Planned for cesarean delivery or contraindication to labor by institutional policy (e.g., active genital herpes infection, placenta previa, vasa previa, history of cavity-entering myomectomy)</li> <li>▪ HIV infection</li> <li>▪ History of mastectomy or contraindication to nipple stimulation</li> <li>▪ Known allergic reactions to components of the electric breast pump or to synthetic oxytocin intravenous solution</li> <li>▪ Significantly impaired consciousness or executive function (e.g., intubated or sedated)</li> <li>▪ Fetus suspected to be at increased risk for neonatal intensive care (e.g., major fetal anomaly which is defined as a prenatally diagnosed anomaly anticipated to require neonatal intensive care unit admission, alloimmunization, and severe fetal growth restriction defined as prenatally suspected estimated fetal weight less than 3<sup>rd</sup> percentile and/or abnormal umbilical artery Doppler assessment showing absent or reversed flow in diastole)</li> </ul>

**Table 2: Schema of subject procedures as part of enrollment and study outcomes**

Participant procedure	At study enrollment (inpatient)	Labor and birth (inpatient)	Postpartum days 1-3 (inpatient)	Postpartum week 2 (follow-up)	Postpartum weeks 4-8 (follow-up)	Postpartum month 6 (follow-up)

Baseline procedures						
Sign medical release forms for participant and soon-to-be newborn						
IFI survey						
EQ-5D survey						
<b>Aim #1: delivery mode</b>						
Intrapartum nipple stimulation diary (study intervention group only)						
<b>Primary outcome:</b> Spontaneous vaginal delivery						
Secondary (exploratory) outcomes: time to delivery, cesarean, OVD, intraamniotic infection/PP endometritis, and PPH						
<b>Aim #2: lactation</b>						
<b>Primary outcome:</b> breastfeeding as sole source of infant nutrition						
Secondary outcomes:						
Survey about intrapartum milk let-down and colostrum collection						
Maximal newborn weight loss						
PIMS survey						
MBFES survey						
Breastfeeding continuation survey						
<b>Aim #3: cost analysis</b>						
Income and education level questions						
Employment status and return to work						
Delivery hospitalization encounter cost (participant)						
Birth hospitalization encounter cost (Infant)						
EQ-5D survey						
TANDI survey						
Infant feeding method						
Breast pump use						
Workplace absenteeism						

and presenteeism						
Household productivity loss						
Postpartum medical care after hospital discharge (participant)						
Postnatal medical care after hospital discharge (infant)						
Travel to and from postpartum care office (participant)						
Travel to and from pediatrician's office (infant)						

Table 3: Sample size estimation for primary outcome

Detectable absolute difference	Anticipated with nipple stimulation therapy	Total Sample size Across Two Study Groups for 90% power
9.4%	79%	988
9.6%	78%	988
9.7%	77%	988
9.8%	76%	988
9.9%	75%	988
10.0%	74%	988
10.1%	73%	988
10.1%	72%	988

## References

1. Martin JA, Hamilton BE, Osterman MJK, Driscoll AK. Births: Final Data for 2019. Natl Vital Stat Rep. 2021 Apr;70(2):1-51. PMID: 33814033.
2. ACOG Practice Bulletin No. 107: Induction of labor. Obstet Gynecol. 2009 Aug;114(2 Pt 1):386-97. PMID: 19623003. doi: 10.1097/AOG.0b013e3181b48ef5.
3. Du Vigneaud V, Ressler C, Trippett S. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. J Biol Chem. 1953 Dec;205(2):949-57. PMID: 13129273.
4. Seitchik J, Amico J, Robinson AG, Castillo M. Oxytocin augmentation of dysfunctional labor. IV. Oxytocin pharmacokinetics. Am J Obstet Gynecol. 1984 Oct 1;150(3):225-8. PMID: 6486188. doi: 10.1016/s0002-9378(84)90355-7.
5. ISMP's list of high-alert medications. Institute for Safe Medical Practices; 2018 [March 13,

2024]; Available from: <https://www.ismp.org/recommendations/high-alert-medications-acute-list>.

6. Clark SL, Simpson KR, Knox GE, Garite TJ. Oxytocin: new perspectives on an old drug. *Am J Obstet Gynecol*. 2009 Jan;200(1):35 e1-6. PMID: 18667171. doi: 10.1016/j.ajog.2008.06.010.
7. Miller LA. Oxytocin, excessive uterine activity, and patient safety: time for a collaborative approach. *J Perinat Neonatal Nurs*. 2009 Jan-Mar;23(1):52-8. PMID: 19209060. doi: 10.1097/JPN.0b013e3181961506.
8. Simpson KR, Knox GE. Oxytocin as a high-alert medication: implications for perinatal patient safety. *MCN Am J Matern Child Nurs*. 2009 Jan-Feb;34(1):8-15; quiz 6-7. PMID: 19104313. doi: 10.1097/01.NMC.0000343859.62828.ee.
9. Phaneuf S, Asboth G, Carrasco MP, Linares BR, Kimura T, Harris A, Bernal AL. Desensitization of oxytocin receptors in human myometrium. *Hum Reprod Update*. 1998 Sep-Oct;4(5):625-33. PMID: 10027616. doi: 10.1093/humupd/4.5.625.
10. Seyb ST, Berka RJ, Socol ML, Dooley SL. Risk of cesarean delivery with elective induction of labor at term in nulliparous women. *Obstet Gynecol*. 1999 Oct;94(4):600-7. PMID: 10511367. doi: 10.1016/s0029-7844(99)00377-4.
11. Miller JM, Jr. Maternal and neonatal morbidity and mortality in cesarean section. *Obstet Gynecol Clin North Am*. 1988 Dec;15(4):629-38. PMID: 3067173.
12. Pardridge WM. Drug transport across the blood-brain barrier. *J Cereb Blood Flow Metab*. 2012 Nov;32(11):1959-72. PMID: 22929442. doi: 10.1038/jcbfm.2012.126.
13. Carson DS, Guastella AJ, Taylor ER, McGregor IS. A brief history of oxytocin and its role in modulating psychostimulant effects. *J Psychopharmacol*. 2013 Mar;27(3):231-47. PMID: 23348754. doi: 10.1177/0269881112473788.
14. Armstrong WE, Hatton GI. The puzzle of pulsatile oxytocin secretion during lactation: some new pieces. *Am J Physiol Regul Integr Comp Physiol*. 2006 Jul;291(1):R26-8. PMID: 16832903. doi: 10.1152/ajpregu.00879.2005.
15. Nickerson K, Bonsness RW, Douglas RG, Condliffe P, Du Vigneaud V. Oxytocin and milk ejection. *Am J Obstet Gynecol*. 1954 May;67(5):1028-34. PMID: 13148259. doi: 10.1016/0002-9378(54)90261-6.
16. Stark EL, Athens ZG, Son M. Intrapartum nipple stimulation therapy for labor induction: a randomized controlled external pilot study of acceptability and feasibility. *Am J Obstet Gynecol MFM*. 2022 Mar;4(2):100575. PMID: 35042047. doi: 10.1016/j.ajogmf.2022.100575.
17. Breastfeeding Report Card, United States, 2020. Centers for Disease Control and Prevention; [March 13, 2024]; Available from: <https://www.cdc.gov/breastfeeding/data/reportcard.htm>.
18. Beaudry M, Dufour R, Marcoux S. Relation between infant feeding and infections during the first six months of life. *J Pediatr*. 1995 Feb;126(2):191-7. PMID: 7844664. doi: 10.1016/s0022-3476(95)70544-9.
19. Kramer MS, Guo T, Platt RW, Sevkovskaya Z, Dzikovich I, Collet JP, et al. Infant growth and health outcomes associated with 3 compared with 6 mo of exclusive breastfeeding. *Am J Clin Nutr*. 2003 Aug;78(2):291-5. PMID: 12885711. doi: 10.1093/ajcn/78.2.291.
20. Paricio Talayero JM, Lizan-Garcia M, Otero Puime A, Benlloch Muncharaz MJ, Beseler Soto B, Sanchez-Palomares M, et al. Full breastfeeding and hospitalization as a result of infections in the first year of life. *Pediatrics*. 2006 Jul;118(1):e92-9. PMID: 16818542. doi: 10.1542/peds.2005-1629.
21. Quigley MA, Kelly YJ, Sacker A. Breastfeeding and hospitalization for diarrheal and respiratory infection in the United Kingdom Millennium Cohort Study. *Pediatrics*. 2007 Apr;119(4):e837-42. PMID: 17403827. doi: 10.1542/peds.2006-2256.
22. Sadeharju K, Knip M, Virtanen SM, Savilahti E, Tauriainen S, Koskela P, et al. Maternal antibodies in breast milk protect the child from enterovirus infections. *Pediatrics*. 2007

May;119(5):941-6. PMID: 17473095. doi: 10.1542/peds.2006-0780.

23. Kramer MS, Aboud F, Mironova E, Vanilovich I, Platt RW, Matush L, et al. Breastfeeding and child cognitive development: new evidence from a large randomized trial. *Arch Gen Psychiatry*. 2008 May;65(5):578-84. PMID: 18458209. doi: 10.1001/archpsyc.65.5.578.

24. Ip S, Chung M, Raman G, Trikalinos TA, Lau J. A summary of the Agency for Healthcare Research and Quality's evidence report on breastfeeding in developed countries. *Breastfeed Med*. 2009 Oct;4 Suppl 1:S17-30. PMID: 19827919. doi: 10.1089/bfm.2009.0050.

25. Mezzacappa ES, Katlin ES. Breast-feeding is associated with reduced perceived stress and negative mood in mothers. *Health Psychol*. 2002 Mar;21(2):187-93. PMID: 11950109.

26. Ystrom E. Breastfeeding cessation and symptoms of anxiety and depression: a longitudinal cohort study. *BMC Pregnancy Childbirth*. 2012 May 23;12:36. PMID: 22621668. doi: 10.1186/1471-2393-12-36.

27. Breastfeeding. World Health Organization; [March 13, 2024]; Available from: [https://www.who.int/health-topics/breastfeeding#tab=tab\\_1](https://www.who.int/health-topics/breastfeeding#tab=tab_1).

28. Breastfeeding Recommendations and Benefits. Centers for Disease Control and Prevention; [March 13, 2024]; Available from: <https://www.cdc.gov/nutrition/infantandtoddlernutrition/breastfeeding/recommendations-benefits.html>.

29. Section on B. Breastfeeding and the use of human milk. *Pediatrics*. 2012 Mar;129(3):e827-41. PMID: 22371471. doi: 10.1542/peds.2011-3552.

30. Li R, Fein SB, Chen J, Grummer-Strawn LM. Why mothers stop breastfeeding: mothers' self-reported reasons for stopping during the first year. *Pediatrics*. 2008 Oct;122 Suppl 2:S69-76. PMID: 18829834. doi: 10.1542/peds.2008-1315i.

31. Brown CR, Dodds L, Legge A, Bryanton J, Semenic S. Factors influencing the reasons why mothers stop breastfeeding. *Can J Public Health*. 2014 May 9;105(3):e179-85. PMID: 25165836. doi: 10.17269/cjph.105.4244.

32. Sandhi A, Lee GT, Chipojola R, Huda MH, Kuo SY. The relationship between perceived milk supply and exclusive breastfeeding during the first six months postpartum: a cross-sectional study. *Int Breastfeed J*. 2020 Jul 17;15(1):65. PMID: 32680551. doi: 10.1186/s13006-020-00310-y.

33. Macdonald PD, Ross SR, Grant L, Young D. Neonatal weight loss in breast and formula fed infants. *Arch Dis Child Fetal Neonatal Ed*. 2003 Nov;88(6):F472-6. PMID: 14602693. doi: 10.1136/fn.88.6.f472.

34. van Dommelen P, van Wouwe JP, Breuning-Boers JM, van Buuren S, Verkerk PH. Reference chart for relative weight change to detect hypernatraemic dehydration. *Arch Dis Child*. 2007 Jun;92(6):490-4. PMID: 16880225. doi: 10.1136/adc.2006.104331.

35. Martens PJ, Romphf L. Factors associated with newborn in-hospital weight loss: comparisons by feeding method, demographics, and birthing procedures. *J Hum Lact*. 2007 Aug;23(3):233-41, quiz 42-5. PMID: 17666534. doi: 10.1177/0890334407303888.

36. Crossland DS, Richmond S, Hudson M, Smith K, Abu-Harb M. Weight change in the term baby in the first 2 weeks of life. *Acta Paediatr*. 2008 Apr;97(4):425-9. PMID: 18363951. doi: 10.1111/j.1651-2227.2008.00685.x.

37. Flaherman VJ, Bokser S, Newman TB. First-day newborn weight loss predicts in-hospital weight nadir for breastfeeding infants. *Breastfeed Med*. 2010 Aug;5(4):165-8. PMID: 20113202. doi: 10.1089/bfm.2009.0047.

38. Flaherman VJ, Kuzniewicz MW, Li S, Walsh E, McCulloch CE, Newman TB. First-day weight loss predicts eventual weight nadir for breastfeeding newborns. *Arch Dis Child Fetal Neonatal Ed*. 2013 Nov;98(6):F488-92. PMID: 23864443. doi: 10.1136/archdischild-2012-303076.

39. Hill PD. The enigma of insufficient milk supply. *MCN Am J Matern Child Nurs*. 1991 Nov-Dec;16(6):312-6. PMID: 1824557.
40. Kools EJ, Thijs C, Kester AD, de Vries H. The motivational determinants of breast-feeding: predictors for the continuation of breast-feeding. *Prev Med*. 2006 Nov;43(5):394-401. PMID: 16872670. doi: 10.1016/j.ypmed.2006.03.012.
41. Dennis CL, Faux S. Development and psychometric testing of the Breastfeeding Self-Efficacy Scale. *Res Nurs Health*. 1999 Oct;22(5):399-409. PMID: 10520192. doi: 10.1002/(sici)1098-240x(199910)22:5<399::aid-nur6>3.0.co;2-4.
42. Dennis CL. The breastfeeding self-efficacy scale: psychometric assessment of the short form. *J Obstet Gynecol Neonatal Nurs*. 2003 Nov-Dec;32(6):734-44. PMID: 14649593. doi: 10.1177/0884217503258459.
43. Lothian J. Promoting, protecting, and supporting normal birth. *J Perinat Educ*. 2004 Spring;13(2):1-5. PMID: 17273381. doi: 10.1624/105812404X109465.
44. Philipp BL, Merewood A, Miller LW, Chawla N, Murphy-Smith MM, Gomes JS, et al. Baby-friendly hospital initiative improves breastfeeding initiation rates in a US hospital setting. *Pediatrics*. 2001 Sep;108(3):677-81. PMID: 11533335. doi: 10.1542/peds.108.3.677.
45. Victora CG, Bahl R, Barros AJ, Franca GV, Horton S, Krasevec J, et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. *Lancet*. 2016 Jan 30;387(10017):475-90. PMID: 26869575. doi: 10.1016/S0140-6736(15)01024-7.
46. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *Trials*. 2010 Mar 24;11:32. PMID: 20334632. doi: 10.1186/1745-6215-11-32.
47. Ludington E, Dexter F. Statistical analysis of total labor pain using the visual analog scale and application to studies of analgesic effectiveness during childbirth. *Anesth Analg*. 1998 Sep;87(3):723-7. PMID: 9728862. doi: 10.1097/00000539-199809000-00045.
48. American College of O, Gynecologists, Society for Maternal-Fetal M, Caughey AB, Cahill AG, Guise JM, Rouse DJ. Safe prevention of the primary cesarean delivery. *Am J Obstet Gynecol*. 2014 Mar;210(3):179-93. PMID: 24565430. doi: 10.1016/j.ajog.2014.01.026.
49. Barber EL, Lundsberg LS, Belanger K, Pettker CM, Funai EF, Illuzzi JL. Indications contributing to the increasing cesarean delivery rate. *Obstet Gynecol*. 2011 Jul;118(1):29-38. PMID: 21646928. doi: 10.1097/AOG.0b013e31821e5f65.
50. Meister MR, Cahill AG, Conner SN, Woolfolk CL, Lowder JL. Predicting obstetric anal sphincter injuries in a modern obstetric population. *Am J Obstet Gynecol*. 2016 Sep;215(3):310 e1-7. PMID: 26902989. doi: 10.1016/j.ajog.2016.02.041.
51. Hodnett ED, Simmons-Tropea DA. The Labour Agency Scale: psychometric properties of an instrument measuring control during childbirth. *Res Nurs Health*. 1987 Oct;10(5):301-10. PMID: 3671777. doi: 10.1002/nur.4770100503.
52. Hollins Martin CJ, Martin CR. Development and psychometric properties of the Birth Satisfaction Scale-Revised (BSS-R). *Midwifery*. 2014 Jun;30(6):610-9. PMID: 24252712. doi: 10.1016/j.midw.2013.10.006.
53. Martin CR, Hollins Martin CJ, Burduli E, Barbosa-Leiker C, Donovan-Batson C, Fleming SE. Measurement and structural invariance of the US version of the Birth Satisfaction Scale-Revised (BSS-R) in a large sample. *Women Birth*. 2017 Aug;30(4):e172-e8. PMID: 27965174. doi: 10.1016/j.wombi.2016.11.006.
54. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. *Br J Psychiatry*. 1987 Jun;150:782-6. PMID: 3651732. doi: 10.1192/bjp.150.6.782.



55. Dozier AM, Brownell EA, Thevenet-Morrison K, Martin H, Hagadorn JI, Howard C. Predicting Maintenance of Any Breastfeeding from Exclusive Breastfeeding Duration: A Replication Study. *J Pediatr*. 2018 Dec;203:197-203 e2. PMID: 30297289. doi: 10.1016/j.jpeds.2018.07.100.
56. Nommsen-Rivers LA, Dewey KG. Development and validation of the infant feeding intentions scale. *Matern Child Health J*. 2009 May;13(3):334-42. PMID: 18473131. doi: 10.1007/s10995-008-0356-y.
57. Nommsen-Rivers LA, Cohen RJ, Chantry CJ, Dewey KG. The Infant Feeding Intentions scale demonstrates construct validity and comparability in quantifying maternal breastfeeding intentions across multiple ethnic groups. *Matern Child Nutr*. 2010 Jul 1;6(3):220-7. PMID: 20929494. doi: 10.1111/j.1740-8709.2009.00213.x.
58. Kent JC, Ashton E, Hardwick CM, Rea A, Murray K, Geddes DT. Causes of perception of insufficient milk supply in Western Australian mothers. *Matern Child Nutr*. 2021 Jan;17(1):e13080. PMID: 32954674. doi: 10.1111/mcn.13080.
59. Leff EW, Jefferis SC, Gagne MP. The development of the Maternal Breastfeeding Evaluation Scale. *J Hum Lact*. 1994 Jun;10(2):105-11. PMID: 7619250. doi: 10.1177/089033449401000217.
60. Riordan JM, Woodley G, Heaton K. Testing validity and reliability of an instrument which measures maternal evaluation of breastfeeding. *J Hum Lact*. 1994 Dec;10(4):231-5. PMID: 7619277. doi: 10.1177/089033449401000416.
61. Consumer Price Index (CPI) Databases. U.S. Bureau of Labor Statistics; [March 14, 2024]; Available from: <https://www.bls.gov/cpi/data.htm>.
62. EQ-5D-5L User Guide: Basic information on how to use the EQ-5D-5L instrument. EuroQol Research Foundation; [March 14, 2024]; Available from: <https://euroqol.org/wp-content/uploads/2021/01/EQ-5D-5LUserguide-08-0421.pdf>.
63. Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, et al. United States Valuation of EQ-5D-5L Health States Using an International Protocol. *Value Health*. 2019 Aug;22(8):931-41. PMID: 31426935. doi: 10.1016/j.jval.2019.02.009.
64. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. *Value Health*. 2015 Mar;18(2):161-72. PMID: 25773551. doi: 10.1016/j.jval.2015.02.001.
65. Petrou S, Kim SW, McParland P, Boyle EM. Mode of Delivery and Long-Term Health-Related Quality-of-Life Outcomes: A Prospective Population-Based Study. *Birth*. 2017 Jun;44(2):110-9. PMID: 27862265. doi: 10.1111/birt.12268.
66. Verstraete J, Ramma L, Jelsma J. Validity and reliability testing of the Toddler and Infant (TANDI) Health Related Quality of Life instrument for very young children. *J Patient Rep Outcomes*. 2020 Nov 9;4(1):94. PMID: 33165662. doi: 10.1186/s41687-020-00251-4.
67. Physician Fee Schedule. Centers for Medicare and Medicaid Services; [March 14, 2024]; Available from: <https://www.cms.gov/medicare/payment/fee-schedules/physician>.
68. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Mahwah, NJ: Lawrence Erlbaum Associates; 1988.
69. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *JAMA*. 2016 Sep 13;316(10):1093-103. PMID: 27623463. doi: 10.1001/jama.2016.12195.
70. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. *Health Econ*. 2005 May;14(5):487-96. PMID: 15497198. doi: 10.1002/hec.944.
71. Alfirevic Z, Keeney E, Dowswell T, Welton NJ, Medley N, Dias S, et al. Which method is best

for the induction of labour? A systematic review, network meta-analysis and cost-effectiveness analysis. *Health Technol Assess*. 2016 Aug;20(65):1-584. PMID: 27587290. doi: 10.3310/hta20650.

72. Kahan BC, Jairath V, Dore CJ, Morris TP. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies. *Trials*. 2014 Apr 23;15:139. PMID: 24755011. doi: 10.1186/1745-6215-15-139.

73. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. *Value Health*. 2022 Jan;25(1):10-31. PMID: 35031088. doi: 10.1016/j.jval.2021.10.008.

74. Chayen B, Tejani N, Verma U. Induction of labor with an electric breast pump. *J Reprod Med*. 1986 Feb;31(2):116-8. PMID: 3959016.

75. Curtis P, Resnick JC, Evens S, Thompson CJ. A comparison of breast stimulation and intravenous oxytocin for the augmentation of labor. *Birth*. 1999 Jun;26(2):115-22. PMID: 10687576. doi: 10.1046/j.1523-536x.1999.00115.x.

76. Stein JL, Bardeguet AD, Verma UL, Tegani N. Nipple stimulation for labor augmentation. *J Reprod Med*. 1990 Jul;35(7):710-4. PMID: 2198350.

77. Dashtinejad E, Abedi P, Afshari P. Comparison of the effect of breast pump stimulation and oxytocin administration on the length of the third stage of labor, postpartum hemorrhage, and anemia: a randomized controlled trial. *BMC Pregnancy Childbirth*. 2018 Jul 7;18(1):293. PMID: 29981576. doi: 10.1186/s12884-018-1832-z.

78. Forster DA, Moorhead AM, Jacobs SE, Davis PG, Walker SP, McEgan KM, et al. Advising women with diabetes in pregnancy to express breastmilk in late pregnancy (Diabetes and Antenatal Milk Expressing [DAME]): a multicentre, unblinded, randomised controlled trial. *Lancet*. 2017 Jun 3;389(10085):2204-13. PMID: 28589894. doi: 10.1016/S0140-6736(17)31373-9.



## Supplementary Files

## Multimedia Appendixes

The submitted proposal/protocol already takes into account all reviewer comments.

URL: <http://asset.jmir.pub/assets/dfe087df309d1e8a28d653f3fde67139.pdf>